Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells - Wikidata - wikimedia - TriplyDB

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

http://www.wikidata.org/entity/Q34877332

about

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy Improving cancer immunotherapy by targeting the STATe of MDSCs Monitoring of the Immune Dysfunction in Cancer Patients Myeloid-derived cells are key targets of tumor immunotherapy Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease.Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system.GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.Myeloid derived suppressor cells are present at high frequency in neonates and suppress in vitro T cell responses.Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis.NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.A signature of immune function genes associated with recurrence-free survival in breast cancer patients.Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.A novel probe for the non-invasive detection of tumor-associated inflammation Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.The invisible arm of immunity in common cancer chemoprevention agents.Myeloid-derived suppressor cells in breast cancer.Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function.Harnessing the immune system for the treatment of breast cancer.Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.Enhancing adoptive immunotherapy of cancer.Immunotherapy of cancer: reprogramming tumor-immune crosstalk.Immune evasion in acute myeloid leukemia: current concepts and future directions.Evolution of Our Understanding of Myeloid Regulatory Cells: From MDSCs to Mregs.Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.The role of oncolytic virus immunotherapies to subvert cancer immune evasion.Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells.Immunotherapy for breast cancer: past, present, and future.DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.Revisiting cancer immunoediting by understanding cancer immune complexity.Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.

P2860

Q27002646-829C02C7-5DFE-468C-A2B6-9ED31AFF9695 Q28066797-E57B5088-CBDE-4C5D-89A6-2B437D4B8E0D Q28072712-B7B413D6-82BD-4FF4-ABDC-7730579F504C Q28388246-16D79504-3A37-45DD-A43D-6DEC78CFCD4B Q34517267-E126A09B-71AF-46A0-89D3-9994C96E9419 Q34590434-5A6E2D18-702E-4BC2-84E5-4ACB0F843287 Q34808155-73781DA2-BBBD-41A1-9E98-13A3B8C5A9F1 Q34983887-43A5D8C9-4522-4193-9911-14E2C7524A97 Q35091491-CE031B3C-6259-443F-84BC-5A3DC881E8F8 Q35239384-8D6C661B-39F9-4831-A38E-A1A51D4738A0 Q35271470-D4FD1817-809B-4A12-B1A1-07B8DEB78F70 Q35567331-83712FE0-ED67-44EB-A90B-1246F70B0C02 Q35956535-4C586B93-CED4-455A-855D-9580C1A11220 Q36199789-E81C5E3D-0531-41DB-915B-BA59FB058E61 Q36464593-80A462E1-BCEC-4220-B737-6B326B6ED75A Q36544980-429D96DC-0243-495A-B6FF-18686ACEB044 Q36694915-026DB938-C8AA-49FA-B086-F5BEAD5C0D01 Q36833481-646EDFDE-2C85-49DF-BA7B-077994AFA78B Q37172099-A1084997-3AB2-470E-8C8D-FFDB4EFC8174 Q37172813-73B31B1C-0CDA-4128-BDEF-6B28A2FC019E Q37405703-80750666-7EC3-4D7A-BFA4-FD8C225C3876 Q37476039-91B8B424-8C52-404C-B9AF-5F7DDDF8C0BC Q37665711-8DC70BE2-2F02-4694-B06A-BB6B7EB25E89 Q37687429-0EF94085-D783-45FD-9351-0C9524F913D6 Q38055479-DCD9AAC8-9799-4554-A892-F97B57034230 Q38172521-CA6539CC-5FF7-4BEE-8933-FBDDA7898797 Q38234941-60934EBA-A351-49B1-8247-7E9D4AAE1384 Q38258842-F1C68DEC-EB9D-42BB-AC89-DDA5D8BBCB01 Q38357137-628ECA4B-DE36-4351-908F-C10EDE20B4AF Q38685586-B3F23686-C162-4DDC-9568-6128D97394CE Q38787696-B5BB81BE-81ED-4EFA-8C55-7FE8AE8FCAE0 Q41247038-DAEC47D4-4E17-4B98-B7AA-41BD6A0EFAB6 Q42731574-953E0AE4-889B-4E75-BC62-BFB377444976 Q52657150-59B51AAB-B650-46A0-A3ED-DF1458BA59E1

P2860

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

http://www.wikidata.org/entity/Q34877332

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@ast

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@en

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@nl

type

label

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@ast

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@en

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@nl

prefLabel

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@ast

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@en

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@nl

P1433

Q34877332-0FEC02E7-1672-47FC-8E44-EC9BEF76DE99

P1476

Q34877332-4359ED35-01E3-46EC-B6FE-77E67B5DA878

P2093

Q34877332-516EEB1A-9D92-49F8-97CD-469BBB8CAE94

Q34877332-554D3A37-1670-43AB-ADF2-70ACC47EAB50

Q34877332-5BBB1C6C-3596-4057-B72D-EECD15DC7CFE

Q34877332-6F32AF40-CC9F-414F-A113-289DD72400A5

Q34877332-7AEB1045-AEB1-404D-946D-010385A75C43

Q34877332-CD13CFBA-769A-4437-9352-721F34276643

P2860

Q34877332-00B9A0A3-F566-47B0-AB3E-C37D7D4FAD21

Q34877332-019B9B27-2A5F-4B9A-8EAC-31ECC639A1D2

Q34877332-07824E54-7D00-401E-9FF3-CE40872DF959

Q34877332-101F2740-C3E1-4AC9-B8D8-1985722D6633

Q34877332-139FCDBC-F1D5-4205-BEE5-E82C95DAF627

Q34877332-1613566A-00A8-484B-A0D9-B129E498ECFD

Q34877332-1881DD23-25B5-4870-8361-5A373D0FAA10

Q34877332-279A87E9-24BA-4CCC-AA03-6947B8A4545B

Q34877332-2E994A97-A8C0-42DC-AFFB-F0BCCCCB926E

Q34877332-30D92CAC-3A4B-45C0-B63E-B9AE42206A29

P2888

Q34877332-76713B5E-C5DE-4567-BA53-921B61C6C209

P304

Q34877332-41E7CD12-D0A2-4460-9EB8-1EE9CB932ADC

P31

Q34877332-B057648D-9B68-4ABB-9302-2AA40B2DA548

P356

Q34877332-E4C16797-9935-40DB-946F-D6A5E101F427

P433

Q34877332-99A6DDFC-4BC7-4478-841F-C18C216A400F

P478

Q34877332-572C3F45-4C12-4B50-BAB0-D466AA02B340

P577

Q34877332-4230254C-FCCF-4587-948F-984873347DEF

P5875

Q34877332-447F04D5-8B4E-4717-A0E4-7A4E73E5B85B

P6179

Q34877332-DE4A6943-84B2-4605-B4F1-E80CF1724960

P698

Q34877332-53E9F3BD-A169-4EEB-850B-E452C5294C73

P932

Q34877332-7C510DBF-AC8B-4345-B040-AB47DF835C98

P356

S00262-008-0609-Z

P1433

Cancer Immunology, Immunotherapy

P1476

Adoptive transfer of HER2/neu- ...... eloid-derived suppressor cells

@en

P2093

Harry D Bear

http://www.w3.org/2001/XMLSchema#string

Johanna K Morales

http://www.w3.org/2001/XMLSchema#string

Laura Graham

http://www.w3.org/2001/XMLSchema#string

Maciej Kmieciak

http://www.w3.org/2001/XMLSchema#string

Marta Feldmesser

http://www.w3.org/2001/XMLSchema#string

Masoud H Manjili

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer regression in patients after transfer of genetically engineered lymphocytes

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

Regulation of immune responses by L-arginine metabolism

Breast cancer vaccines: a clinical reality or fairy tale?

Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers.

Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

IL-15 is a growth factor and an activator of CD8 memory T cells.

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

Cytokine control of memory T-cell development and survival.

Mechanisms and functional significance of tumour-induced dendritic-cell defects.

P2888

s00262-008-0609-z

P304

941-953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-008-0609-Z

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23446520

http://www.w3.org/2001/XMLSchema#string

P6179

1046127303

http://www.w3.org/2001/XMLSchema#string

P698

18979098

http://www.w3.org/2001/XMLSchema#string

P932

3083860

http://www.w3.org/2001/XMLSchema#string